🇧🇪 ARGX.BR — argenx SE
Salud Compra fuertePrecio actual
788,80 EUR
Máx. histórico
912,40
61 días
Caída desde máximo
-13,55%
Rango 52 semanas
568,40 – 925,00
Variación hoy
+0,61%
Cierre anterior
784,00
Rango de hoy
776,60 – 798,60
Volumen hoy
92.256
Peor caída histórica
-39,26%
21/07/2023 → 21/12/2023
Recuperado en 262 días
Volatilidad anualizada ⓘ
43,78%
- Nombre completo
- argenx SE
- Divisa
- EUR
- Mercado
- Brussels
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 1.863
- PER ⓘ
- 31,74 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 1.001,51 EUR (puede no estar actualizado)
- Primera cotización
- 10/07/2014
- Precio actualizado
- hace 21 horas
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 12/03/2025 | 534,00 | 543,20 | 532,80 | 540,80 | +3,40% | 1,95% | 94.579 |
| 11/03/2025 | 521,00 | 527,40 | 516,20 | 523,00 | -1,54% | 2,15% | 135.597 |
| 10/03/2025 | 550,00 | 552,60 | 527,00 | 531,20 | -4,36% | 4,65% | 115.402 |
| 07/03/2025 | 568,00 | 571,20 | 554,00 | 555,40 | -3,94% | 3,03% | 90.749 |
| 06/03/2025 | 594,80 | 595,00 | 575,00 | 578,20 | -2,36% | 3,36% | 91.501 |
| 05/03/2025 | 587,40 | 596,20 | 585,60 | 592,20 | +0,14% | 1,80% | 91.615 |
| 04/03/2025 | 597,00 | 607,20 | 588,00 | 591,40 | -2,05% | 3,22% | 72.376 |
| 03/03/2025 | 600,40 | 615,00 | 597,40 | 603,80 | +1,11% | 2,93% | 59.555 |
| 28/02/2025 | 598,80 | 604,40 | 586,00 | 597,20 | -2,32% | 3,07% | 325.046 |
| 27/02/2025 | 616,00 | 625,80 | 596,00 | 611,40 | +1,83% | 4,84% | 55.970 |
| 26/02/2025 | 597,00 | 603,60 | 594,40 | 600,40 | +0,33% | 1,54% | 63.077 |
| 25/02/2025 | 604,00 | 613,20 | 597,60 | 598,40 | -0,73% | 2,58% | 102.243 |
| 24/02/2025 | 612,00 | 620,00 | 601,40 | 602,80 | -2,65% | 3,04% | 52.837 |
| 21/02/2025 | 615,80 | 621,80 | 613,00 | 619,20 | +0,55% | 1,43% | 42.090 |
| 20/02/2025 | 610,00 | 618,00 | 608,80 | 615,80 | -0,45% | 1,51% | 42.329 |
| 19/02/2025 | 612,40 | 618,60 | 608,80 | 618,60 | +0,78% | 1,60% | 39.420 |
| 18/02/2025 | 616,40 | 618,60 | 607,20 | 613,80 | -0,13% | 1,85% | 44.408 |
| 17/02/2025 | 612,60 | 616,00 | 609,80 | 614,60 | +1,12% | 1,01% | 27.421 |
| 14/02/2025 | 623,80 | 625,40 | 601,80 | 607,80 | -2,13% | 3,78% | 69.507 |
| 13/02/2025 | 627,80 | 627,80 | 618,20 | 621,00 | -0,42% | 1,53% | 36.543 |
| 12/02/2025 | 618,80 | 624,00 | 613,40 | 623,60 | +0,68% | 1,71% | 48.584 |
| 11/02/2025 | 628,80 | 632,00 | 612,20 | 619,40 | -2,21% | 3,15% | 51.201 |
| 10/02/2025 | 627,40 | 640,60 | 627,40 | 633,40 | +0,22% | 2,10% | 60.968 |
| 07/02/2025 | 630,00 | 636,40 | 628,60 | 632,00 | -0,94% | 1,24% | 44.055 |
| 06/02/2025 | 647,00 | 651,80 | 632,80 | 638,00 | -0,50% | 2,94% | 57.678 |
| 05/02/2025 | 628,80 | 644,00 | 626,60 | 641,20 | +1,55% | 2,77% | 60.615 |
| 04/02/2025 | 639,20 | 643,40 | 627,40 | 631,40 | -0,60% | 2,50% | 42.094 |
| 03/02/2025 | 634,80 | 638,80 | 630,40 | 635,20 | -1,21% | 1,32% | 49.314 |
| 31/01/2025 | 642,20 | 647,40 | 638,40 | 643,00 | +1,26% | 1,40% | 47.248 |
| 30/01/2025 | 636,60 | 640,40 | 627,40 | 635,00 | +0,54% | 2,04% | 51.238 |